Content about Switzerland

June 1, 2012

While headlines in the past two weeks warned consumers that calcium supplementation could increase the risk of cardiovascular disease, authors of the study that prompted those headlines — published last month in the peer-reviewed journal Heart — identified four significant confounding factors in the design of the study.

ZURICH, Switzerland — While headlines in the past two weeks warned consumers that calcium supplementation could increase the risk of cardiovascular disease, authors of the study that prompted those headlines — published last month in the peer-reviewed journal Heart — identified four significant confounding factors in the design of the study.

For example, the dietary data contained measurement errors and could not adequately account for long-term variation in calcium intake due to changes in diet.

May 10, 2012

Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

Watson announced the formation of the global integration management office, which will report directly to president and CEO Paul Bisaro and focus on integrating the Zug, Switzerland-based generic drug maker, which Watson announced it would acquire last month.

May 2, 2012

Novartis' generics division has acquired Fougera Pharmaceuticals, the company said Wednesday.

BASEL, Switzerland — Novartis' generics division has acquired Fougera Pharmaceuticals, the company said Wednesday.

Sandoz announced the acquisition of Melville, N.Y.-based Fougera for $1.525 billion in cash. Fougera specializes in generic dermatology drugs, and Sandoz said the acquisition would make it the world's largest company in the space.

April 19, 2012

The Council for Responsible Nutrition-International on Thursday named several new officers to its board of directors.

MANNO, SWITZERLAND — The Council for Responsible Nutrition-International on Thursday named several new officers to its board of directors.

Herbalife's John Venardos has been elected chairman and Tyler Whitehead of Nu Skin Enterprises has been elected vice chairman. The Vitamin Shoppe's David Morrison has been named secretary; Carl Hastings of Reliv International has been named treasurer; and Mark LeDoux of Natural Alternatives International has become the immediate past chairman.

April 18, 2012

Roche has decided not to buy diagnostics firm Illumina, the drug maker said Wednesday.

BASEL, Switzerland — Roche has decided not to buy diagnostics firm Illumina, the drug maker said Wednesday.

Roche said it had decided not to extend its $51-per-share offer for Illumina following the reelection of Illumina's incumbent directors. Roche offered to buy Illumina for $44.50 per share in January, increasing the offer to $51 on March 29. The company took the offer directly to shareholders earlier this month after Illumina's board rejected it.

April 17, 2012

A U.S. drug maker has made a deal with a Swiss company to manufacture and sell a new osteoporosis treatment in North America.

SAN ANTONIO — A U.S. drug maker has made a deal with a Swiss company to manufacture and sell a new osteoporosis treatment in North America.

Mission Pharmacal announced Tuesday a patent and technology licensing agreement with Freienbach, Switzerland-based EffRx Pharmaceuticals for Binosto (alendronate sodium) effervescent tablets in the United States and Canada. Financial terms were not disclosed.

March 15, 2012

The Food and Drug Administration approved an effervescent tablet for treating osteoporosis.

FREIENBACH, Switzerland — The Food and Drug Administration approved an effervescent tablet for treating osteoporosis.

EffRx Pharmaceuticals announced the FDA approval of Binosto (alendronate sodium), a strawberry-flavored tablet designed to dissolve in water that the company called the first treatment of its kind. The drug is designed to treat osteoporosis in menopausal women and increase bone mass in men with osteoporosis. EffRx expects to launch Binosto in third quarter 2012.

December 22, 2011

A Swiss drug maker is acquiring the U.S. rights for several GlaxoSmithKline drugs.

ZUG, Switzerland — A Swiss drug maker is acquiring the U.S. rights for several GlaxoSmithKline drugs.

Covis Pharma Sarl announced Thursday that it had acquired the rights to the antibiotic Fortaz (ceftazidime), the antibiotic Zinacef (cefuroxime), the heart arrhythmia drug Lanoxin (digoxin), the antidepressant Parnate (tranylcypromine sulfate) and the gastroesophogeal reflux disease drug Zantac (ranitidine hydrochloride). GSK will retain rights to the drugs outside the United States.

Financial terms of the deal were not disclosed.

November 10, 2011

The Food and Drug Administration has accepted a new drug application for a skin cancer treatment developed by Roche.

BASEL, Switzerland — The Food and Drug Administration has accepted a new drug application for a skin cancer treatment developed by Roche.

Roche said that the FDA accepted its NDA for vismodegib, designed to treat advanced basal cell carcinoma in adults for whom surgery is considered inappropriate. The application was granted priorit review status and has a confirmed action date of March 8, 2012.

November 3, 2011

Procter & Gamble on Thursday announced the creation of a new partnership and joint venture with Teva Pharmaceutical Industries to be named PGT Healthcare.

CINCINNATI — Procter & Gamble on Thursday announced the creation of a new partnership and joint venture with Teva Pharmaceutical Industries to be named PGT Healthcare.

“This unique and transformational partnership creates one of the broadest and deepest [over-the-counter] product portfolios and geographic footprints in the industry,” Teva president and CEO Shlomo Yanai said. “Each company’s leading brands will experience tremendous growth by combining our strengths. We will be better together.”

September 29, 2011

Roche has received approval from the Food and Drug Administration for its new generation of blood-glucose test strips.

BASEL, Switzerland — Roche has received approval from the Food and Drug Administration for its new generation of blood-glucose test strips.

Roche said that its Accu-Chek Aviva Plus test strips are maltose-independent test strips that are designed to prevent the interference of maltose on blood-sugar readings, which can occur in rare cases when drugs containing or metabolizing to maltose are parenterally administered.

The Accu-Chek Aviva Plus test strip is cleared for patient self-monitoring of blood glucose and can be used with the Accu-Chek Aviva system.

September 28, 2011

Nestlé EVP and CFO Jim Singh will retire in March 2012 after 35 years with the company.

VEVEY, Switzerland — Nestlé EVP and CFO Jim Singh will retire in March 2012 after 35 years with the company.

Replacing Singh is Wan Ling Martello, who currently serves as Walmart's EVP global e-commerce of emerging markets. She will succeed Singh on April 1, 2012.

August 8, 2011

An investigational treatment made by Roche for asthma increased lung function in patients who could not adequately control their disease with inhaled corticosteroids, according to results of a mid-stage clinical trial.

BASEL, Switzerland — An investigational treatment made by Roche for asthma increased lung function in patients who could not adequately control their disease with inhaled corticosteroids, according to results of a mid-stage clinical trial.

May 24, 2011

Alterna, a marketer of personal care products and therapeutic over-the-counter medicines, has signed a new trademark and know-how license agreement with Spirig Pharma AG of Egerkingen, Switzerland, which expands Alterna's exclusive rights to distribute Kerasal one-step exfoliating moisturizing foot ointment to 80 countries outside of North America.

WHIPPANY, N.J. — Alterna, a marketer of personal care products and therapeutic over-the-counter medicines, has signed a new trademark and know-how license agreement with Spirig Pharma AG of Egerkingen, Switzerland, which expands Alterna's exclusive rights to distribute Kerasal one-step exfoliating moisturizing foot ointment to 80 countries outside of North America.

Alterna already owns the Kerasal brand in North America, having fully acquired all rights to trademarks and product technology in 2006.

March 24, 2011

The Food and Drug Administration has extended its regulatory review period for Novartis' new drug application for its once-daily, long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, as well as chronic bronchitis and/or emphysema, the drug maker said.

BASEL, Switzerland — The Food and Drug Administration has extended its regulatory review period for Novartis' new drug application for its once-daily, long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, as well as chronic bronchitis and/or emphysema, the drug maker said.

March 8, 2011

Nestle is looking to boost its coffee business.

VEVEY, Switzerland — Nestle is looking to boost its coffee business.

The company, which recently reported that its soluble coffee was a key growth driver during 2010 across all regions, said the combined performances of single-serve coffee brands Nespresso and Nescafé Dolce Gusto strengthened its leadership in the dynamic portioned coffee market. Nestle added that its Nespresso brand reached $3.24 billion in annual sales for the first time.

February 17, 2011

Novartis on Thursday morning named Naomi Kelman head of the Novartis OTC division, effective March 2. She will report directly to Joseph Jimenez, Novartis CEO.

BASEL, Switzerland — Novartis on Thursday morning named Naomi Kelman head of the Novartis OTC division, effective March 2. She will report directly to Joseph Jimenez, Novartis CEO.

The Novartis OTC and animal health businesses will become separate Novartis divisions, in addition to the pharmaceuticals, Sandoz (generics), vaccines and diagnostics divisions. As previously announced, following the completion of the merger between Novartis and Alcon, CIBA Vision and Novartis ophthalmic medicines will be merged into the new Alcon eye care division of Novartis.

February 2, 2011

Nestlé Health Sciences completed its acquisition of a company that develops "medical foods" for such medical conditions as kidney disease, inflammatory bowel disease and colon cancer.

LUTRY, Switzerland — Nestlé Health Sciences completed its acquisition of a company that develops "medical foods" for such medical conditions as kidney disease, inflammatory bowel disease and colon cancer.

February 1, 2011

The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.

BASEL, Switzerland — The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.

Novartis announced the approval of Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) for active immunization to prevent certain forms of meningococcal disease caused by Neisseria meningitidis in children ages 2 to 10 years. The FDA approved the vaccine last year for use in adolescents and adults ages 11 to 55 years.

January 27, 2011

Swiss drug maker Novartis posted sales of $14.2 billion for fourth quarter 2010 and $50.6 billion for the year as a whole, according to an earnings report released Thursday.

BASEL, Switzerland — Swiss drug maker Novartis posted sales of $14.2 billion for fourth quarter 2010 and $50.6 billion for the year as a whole, according to an earnings report released Thursday.

That compared with sales of $12.9 billion and $44.3 billion during fourth quarter 2009 and 2009 as a whole, respectively. Profits for the year were nearly $10 billion, an 18% increase from $8.4 billion in 2009, though profits for the quarter decreased by 2%, from fourth quarter 2009’s $2.32 billion to $2.27 billion in fourth quarter 2010.

January 18, 2011

Generic drug maker Sandoz has started a mid-stage clinical trial of a monoclonal antibody used to treat cancer and autoimmune disease, the company said.

HOLZKIRCHEN, Switzerland — Generic drug maker Sandoz has started a mid-stage clinical trial of a monoclonal antibody used to treat cancer and autoimmune disease, the company said.

Sandoz (pronounced “SAN-doh”), the generics arm of Swiss drug maker Novartis, announced the start of a phase-2 trial of rituximab, a biosimilar of Genentech’s Rituxan, used to treat such conditions as non-Hodgkin’s lymphoma and rheumatoid arthritis.

January 17, 2011

Roche CFO Erich Hunziker will retire from the company at the end of March, the Swiss drug maker said Monday.

BASEL, Switzerland — Roche CFO Erich Hunziker will retire from the company at the end of March, the Swiss drug maker said Monday.

Hunziker was appointed CFO and a member of the corporate executive committee in 2001, and last year took on the additional role of chief information officer.

Alan Hippe, a former executive from German tire maker Continental and manufacturer ThyssenKrupp, will replace Hunziker as CFO.

December 20, 2010

With the new year approaching, Nestlé Health Science S.A. and the Nestlé Institute of Health Sciences — both created to pioneer a new industry between food and pharma — became operational.

VEVEY, Switzerland — With the new year approaching, Nestlé Health Science S.A. and the Nestlé Institute of Health Sciences — both created to pioneer a new industry between food and pharma — became operational.

December 15, 2010

Novartis on Wednesday announced that its merger agreement with Alcon has been settled to the tune of $12.9 billion. The new $8.7 billion Alcon eye care division, which includes CIBA Vision and selected ophthalmic medicines, will be led by current Alcon president and CEO Kevin Buehler.

BASEL, Switzerland — Novartis on Wednesday announced that its merger agreement with Alcon has been settled to the tune of $12.9 billion. The new $8.7 billion Alcon eye care division, which includes CIBA Vision and selected ophthalmic medicines, will be led by current Alcon president and CEO Kevin Buehler.

Shares of Novartis were up 7.6% to more than $60 in early morning trading.

"The full merger is the logical conclusion of our initial strategic investment in Alcon,” stated Daniel Vasella, Novartis chairman.

November 17, 2010

MinuteClinic, CVS Caremark's network of walk-in medical clinics, was highlighted as a breakthrough innovator in...

WOONSOCKET, R.I. — MinuteClinic, CVS Caremark's network of walk-in medical clinics, was highlighted as a breakthrough innovator in healthcare delivery by the World Economic Forum's Innovative Health Care Delivery Project.

In addition, MinuteClinic president and CVS Caremark SVP and associate chief medical officer Andrew Sussman presented MinuteClinic's approach to care at a World Economic Forum satellite session attended by healthcare experts, regulatory representatives, researchers and other innovators in Montreux, Switzerland, this week.